{"DataElement":{"publicId":"6690761","version":"1","preferredName":"Amyloidosis Classification Type","preferredDefinition":"A description of the amyloidosis classification.","longName":"6690752v1.0:6690755v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"6690752","version":"1","preferredName":"Amyloidosis Classification","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"3003939v1.0:2321361v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"3003939","version":"1","preferredName":"Amyloidosis","preferredDefinition":"A group of diseases in which protein is deposited in specific organs (localized amyloidosis) or throughout the body (systemic amyloidosis). Amyloidosis may be either primary (with no known cause) or secondary (caused by another disease, including some types of cancer). Generally, primary amyloidosis affects the nerves, skin, tongue, joints, heart, and liver; secondary amyloidosis often affects the spleen, kidneys, liver, and adrenal glands.","longName":"C2868","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7E2F4315-122C-5E22-E040-BB89AD43496E","latestVersionIndicator":"Yes","beginDate":"2010-01-27","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-01-27","modifiedBy":"ONEDATA","dateModified":"2010-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"86550CCC-0D3B-7C5C-E053-F662850ABA26","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-12","modifiedBy":"KUMMEROA","dateModified":"2020-01-30","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6690755","version":"1","preferredName":"Amyloidosis Type","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands._Something distinguishable as an identifiable class based on common qualities.","longName":"6690755v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"AHL amyloidosis","valueDescription":"AHL Amyloidosis","ValueMeaning":{"publicId":"6690756","version":"1","preferredName":"AHL Amyloidosis","longName":"6690756","preferredDefinition":"An extremely rare type of amyloidosis characterized by the monoclonal deposition of immunoglobulin heavy chain and light chain fragments in organs and tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AHL Amyloidosis","conceptCode":"C158964","definition":"An extremely rare type of amyloidosis characterized by the monoclonal deposition of immunoglobulin heavy chain and light chain fragments in organs and tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86550482-1009-7C64-E053-F662850ABED1","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86550482-1022-7C64-E053-F662850ABED1","beginDate":"2019-04-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"},{"value":"AH amyloidosis","valueDescription":"AH Amyloidosis","ValueMeaning":{"publicId":"6690757","version":"1","preferredName":"AH Amyloidosis","longName":"6690757","preferredDefinition":"A rare type of amyloidosis characterized by the monoclonal deposition of immunoglobulin heavy chain fragments in organs and tissues. It is associated with plasma cell or B-cell lymphoproliferative disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AH Amyloidosis","conceptCode":"C158962","definition":"A rare type of amyloidosis characterized by the monoclonal deposition of immunoglobulin heavy chain fragments in organs and tissues. It is associated with plasma cell or B-cell lymphoproliferative disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86550482-102E-7C64-E053-F662850ABED1","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86550482-1047-7C64-E053-F662850ABED1","beginDate":"2019-04-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"},{"value":"AL amyloidosis","valueDescription":"Primary Amyloidosis","ValueMeaning":{"publicId":"2838692","version":"1","preferredName":"Primary Amyloidosis","longName":"2838692","preferredDefinition":"A plasma cell neoplasm that secretes an abnormal immunoglobulin, which deposits in various tissues and forms a beta-pleated sheet structure that binds Congo red dye with characteristic birefringence.  The sites of involvement include heart, liver, kidney, gut, tongue, nerves, and bone. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Amyloidosis","conceptCode":"C3819","definition":"A plasma cell neoplasm that secretes an abnormal immunoglobulin, which deposits in tissues and forms a beta-pleated sheet structure that binds Congo red dye with characteristic birefringence. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-96E1-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86550482-105B-7C64-E053-F662850ABED1","beginDate":"2019-04-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6690754","version":"1","preferredName":"Amyloidosis Type","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.:Something distinguishable as an identifiable class based on common qualities.","longName":"C2868:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86550482-0FE0-7C64-E053-F662850ABED1","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"86550482-0FF1-7C64-E053-F662850ABED1","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-12","modifiedBy":"KUMMEROA","dateModified":"2020-01-30","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"TDIS_PCD_amylds_class_spec","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the amyloidosis clas","type":"Preferred Question Text","description":"What was the amyloidosis classification?","url":null,"context":"NHLBI"},{"name":"Specify Amyloidosis classification","type":"Alternate Question Text","description":"Specify Amyloidosis classification","url":null,"context":"NHLBI"},{"name":"Specify Amyloidosis classification","type":"Application Standard Question Text","description":"Specify Amyloidosis classification","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8655427D-0F6E-768E-E053-F662850AB416","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-12","modifiedBy":"KUMMEROA","dateModified":"2020-01-30","changeDescription":". System generated def displayed as alt def.; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}